

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human CHD1L in direct ELISAs and Western blots. In direct ELISAs, less than 3% cross-reactivity with recombinant human (rh) CHD1 and rhCHD5 is observed.
Source	Polyclonal Sheep IgG
Purification	Antigen Affinity-purified
Immunogen	Chinese hamster ovary cell line CHO-derived recombinant human CHD1L Arg759-Lys879 Accession # Q86WJ1
Conjugate	Alexa Fluor 405 Excitation Wavelength: 405 nm Emission Wavelength: 421 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Western Blot Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

CHD-1L (Chromohelicase/ATPase DNA-binding protein 1-Like; also ALC-1) is a 98-118 kDa member of the SNF2/RAD54 helicase family of proteins. It is expressed in hepatocytes, possesses ATPase activity, and likely promotes chromatin remodeling at sites of DNA damage. It also is considered an oncogene. CHD-1L upregulates ARHGEF9 transcription, an action that promotes Cdc42 activity with accompanying filopodia formation and EMT. It also binds apoptosis-mediating Nur77, blocking its migration from nucleus-to-mitochondria. Human CHD-1L is 897 amino acids (aa) in length. It contains a helicase ATP-binding domain (aa 58-223), a C-terminal helicase domain (aa 351-513), a coiled-coil region (aa 38-675) and one Macro domain that binds poly-ADP-ribose and targets DNA damage sites (aa 704-897). There are at least two Ser/Thr phosphorylation sites. There are multiple potential splice variants. One isoform contains an alternative start site at Met114, a second isoform possesses a deletion of aa 43-246, a third isoform shows a three aa substitution for aa 363-897, and a fourth isoform combines a 16 aa insertion after Arg386 with a five aa substitution for aa 425-897. Over aa 759-879, human CHD-1L shares 94% aa identity with mouse CHD-1L.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.